<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039075</url>
  </required_header>
  <id_info>
    <org_study_id>CQ-Metformin-2016</org_study_id>
    <nct_id>NCT03039075</nct_id>
  </id_info>
  <brief_title>Metformin SR Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes</brief_title>
  <acronym>CQM-2016</acronym>
  <official_title>Comparison of Metformin Hydrochloride Sustained-release Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD is
      approved by China Food And Drug Administration (cFDA). Whether its efficacy and safety are
      equal to Glucophage is unclear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To perform a RCT for the comparison between Metformin hydrochloride sustained-release tablets
      made in Conquer pharmaceutical co., LTD and Glucophage .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of nausea, diarrhea</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of weight</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of intestinal flora proportion</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of LDL, HDL, TG, TC</measure>
    <time_frame>12 weeks</time_frame>
    <description>blood lipid</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin SR Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The original drug of metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin SR Tablet</intervention_name>
    <description>Metformin SR Tablet made in Conquer pharmaceutical co., LTD</description>
    <arm_group_label>Metformin SR Tablet</arm_group_label>
    <arm_group_label>Glucophage</arm_group_label>
    <other_name>DuLeNing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Well informed of the procedures of this trial and informed consent is obtained

          2. Voluntarily accept standardized treatment 3.18-75 years old, gender is not limited

        4.Newly diagnosed as type 2 diabetes and have not yet received any hypoglycemic therapy
        5.Unable to control the blood glucose by diet and exercise: 7.5% ≤HbA1c ≤11.0%, in
        screening and before randomization 6.BMI: 19~35 kg/m2 7.Well compliance 8.Capable of self
        blood Glucose monitoring

        Exclusion Criteria:

          1. Pregnant or lactating

          2. Type 1 diabetes

          3. Poor blood glucose control（HbA1c&gt;11%）

          4. A history of malignant tumor

          5. Abnormal liver or renal function (defined as alanine aminotransferase(ALT)&gt;2.5 times
             higher than normal range,or eGFR&lt;45 mL/min per 1•73 m²)

          6. Poor blood pressure control [systolic blood pressure(SBP)&gt;180mmHg,or diastolic blood
             pressure(DBP)&gt;110mmHg]

          7. With severe heart disease,cardiac function worse than grade II,anemia(Hb&lt;9.0g/d1)

          8. Continuous use of antidiabetic drugs more than one week in recent 3 months

          9. History of acute metabolic complications in recent 6 months

         10. Blood routine test indicates that the white blood cell count(WBC) &lt;3*109/l

         11. Body Mass Index(BMI)&lt;18.5 or ≥35kg/m2

         12. Drug or alcohol abuse

         13. Accompanying mental disorder who can't collaborate

         14. Abnormal digestion and absorption function

         15. Other endocrine diseases

         16. Other chronic diseases needed long-term glucocorticoid treatment

         17. With severe infection, immune dysfunction

         18. A history of metformin allergies or allergic constitution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lilin Gong</last_name>
    <phone>+86 023-89011552</phone>
    <email>173183841@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, PhD</last_name>
      <phone>+86 23 89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488. Epub 2015 Aug 18.</citation>
    <PMID>26285584</PMID>
  </reference>
  <reference>
    <citation>Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH, Demirkan A, Yu Z, Ried JS, Haller T, Heier M, Campillos M, Fobo G, Stark R, Holzapfel C, Adam J, Chi S, Rotter M, Panni T, Quante AS, He Y, Prehn C, Roemisch-Margl W, Kastenmüller G, Willemsen G, Pool R, Kasa K, van Dijk KW, Hankemeier T, Meisinger C, Thorand B, Ruepp A, Hrabé de Angelis M, Li Y, Wichmann HE, Stratmann B, Strauch K, Metspalu A, Gieger C, Suhre K, Adamski J, Illig T, Rathmann W, Roden M, Peters A, van Duijn CM, Boomsma DI, Meitinger T, Wang-Sattler R. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care. 2015 Oct;38(10):1858-67. doi: 10.2337/dc15-0658. Epub 2015 Aug 5.</citation>
    <PMID>26251408</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

